CA1100037A - Antigene (anti hb.sub.c) depose sur une substance en phase solide - Google Patents

Antigene (anti hb.sub.c) depose sur une substance en phase solide

Info

Publication number: CA1100037A
Authority: CA; Canada
Prior art keywords: hbc; dane; solid phase; core; bead
Prior art date: 1977-03-11
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

CA296,740A

Other languages

English (en)

Inventor

Chung-Mei Ling

Lacy R. Overby

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Abbott Laboratories

Original Assignee

Abbott Laboratories

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1977-03-11

Filing date

1978-02-10

Publication date

1981-04-28

1978-02-10 Application filed by Abbott Laboratories filed Critical Abbott Laboratories

1981-04-28 Application granted granted Critical

1981-04-28 Publication of CA1100037A publication Critical patent/CA1100037A/fr

Status Expired legal-status Critical Current

Links

239000007790 solid phase Substances 0.000 title claims description 15
239000003153 chemical reaction reagent Substances 0.000 claims abstract description 17
239000011324 bead Substances 0.000 claims description 28
210000004369 blood Anatomy 0.000 claims description 9
239000008280 blood Substances 0.000 claims description 9
238000001514 detection method Methods 0.000 claims description 9
101710132601 Capsid protein Proteins 0.000 claims description 8
238000003018 immunoassay Methods 0.000 claims description 7
241000700721 Hepatitis B virus Species 0.000 claims description 6
239000004793 Polystyrene Substances 0.000 claims description 3
239000011521 glass Substances 0.000 claims description 3
239000004033 plastic Substances 0.000 claims description 3
229920002223 polystyrene Polymers 0.000 claims description 3
239000000470 constituent Substances 0.000 claims description 2
210000002966 serum Anatomy 0.000 abstract description 16
238000003556 assay Methods 0.000 abstract description 7
239000002245 particle Substances 0.000 description 29
238000000034 method Methods 0.000 description 15
239000000523 sample Substances 0.000 description 14
238000003127 radioimmunoassay Methods 0.000 description 12
239000003550 marker Substances 0.000 description 7
241000700605 Viruses Species 0.000 description 6
239000000427 antigen Substances 0.000 description 6
102000036639 antigens Human genes 0.000 description 6
108091007433 antigens Proteins 0.000 description 6
238000002360 preparation method Methods 0.000 description 6
239000007787 solid Substances 0.000 description 6
239000000243 solution Substances 0.000 description 6
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 5
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 5
108060003951 Immunoglobulin Proteins 0.000 description 5
241001465754 Metazoa Species 0.000 description 5
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
229930006000 Sucrose Natural products 0.000 description 5
230000000694 effects Effects 0.000 description 5
102000018358 immunoglobulin Human genes 0.000 description 5
238000000746 purification Methods 0.000 description 5
239000005720 sucrose Substances 0.000 description 5
238000005406 washing Methods 0.000 description 5
210000002381 plasma Anatomy 0.000 description 4
238000012360 testing method Methods 0.000 description 4
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 4
239000011248 coating agent Substances 0.000 description 3
238000000576 coating method Methods 0.000 description 3
230000002860 competitive effect Effects 0.000 description 3
239000003599 detergent Substances 0.000 description 3
208000002672 hepatitis B Diseases 0.000 description 3
230000001900 immune effect Effects 0.000 description 3
230000002688 persistence Effects 0.000 description 3
208000034657 Convalescence Diseases 0.000 description 2
241001354529 Lasthenia Species 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
239000007853 buffer solution Substances 0.000 description 2
AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
239000000969 carrier Substances 0.000 description 2
230000000295 complement effect Effects 0.000 description 2
239000007771 core particle Substances 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
230000035931 haemagglutination Effects 0.000 description 2
208000006454 hepatitis Diseases 0.000 description 2
231100000283 hepatitis Toxicity 0.000 description 2
230000036039 immunity Effects 0.000 description 2
238000011534 incubation Methods 0.000 description 2
239000012678 infectious agent Substances 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
230000002458 infectious effect Effects 0.000 description 2
238000002616 plasmapheresis Methods 0.000 description 2
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
241000700198 Cavia Species 0.000 description 1
241000700199 Cavia porcellus Species 0.000 description 1
GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
GJAARPKBDFKHFS-UHFFFAOYSA-N Gerin Natural products COC(=O)C(=C)C1CC2C(=C)C(=O)C=CC2(C)CC1OC(=O)C GJAARPKBDFKHFS-UHFFFAOYSA-N 0.000 description 1
102000004895 Lipoproteins Human genes 0.000 description 1
108090001030 Lipoproteins Proteins 0.000 description 1
241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
241000282577 Pan troglodytes Species 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
239000010836 blood and blood product Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
238000000635 electron micrograph Methods 0.000 description 1
238000001493 electron microscopy Methods 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
210000003494 hepatocyte Anatomy 0.000 description 1
230000000521 hyperimmunizing effect Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000000984 immunochemical effect Effects 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
230000001524 infective effect Effects 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
238000005259 measurement Methods 0.000 description 1
239000000203 mixture Substances 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
239000013642 negative control Substances 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
229940111202 pepsin Drugs 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
230000035484 reaction time Effects 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
238000004062 sedimentation Methods 0.000 description 1
238000010998 test method Methods 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
210000002845 virion Anatomy 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
- G01N33/5761—Hepatitis B
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Hematology (AREA)
Biochemistry (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Organic Chemistry (AREA)
Cell Biology (AREA)
Gastroenterology & Hepatology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Microbiology (AREA)
Biotechnology (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Virology (AREA)
Food Science & Technology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Communicable Diseases (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

CA296,740A 1977-03-11 1978-02-10 Antigene (anti hb.sub.c) depose sur une substance en phase solide Expired CA1100037A (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US77728377A	1977-03-11	1977-03-11
US777,283		1977-03-11

Publications (1)

Publication Number	Publication Date
CA1100037A true CA1100037A (fr)	1981-04-28

Family

ID=25109817

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA296,740A Expired CA1100037A (fr)	1977-03-11	1978-02-10	Antigene (anti hb.sub.c) depose sur une substance en phase solide

Country Status (8)

Country	Link
JP (1)	JPS53113009A (fr)
AU (1)	AU3332278A (fr)
CA (1)	CA1100037A (fr)
DE (1)	DE2810506A1 (fr)
FR (1)	FR2383446A1 (fr)
GB (1)	GB1576981A (fr)
NL (1)	NL7802259A (fr)
SE (1)	SE7802461L (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4241175A (en) *	1978-12-18	1980-12-23	Merck & Co., Inc.	Assay for hepatitis B core antibody
CA1148859A (fr) *	1979-06-14	1983-06-28	Lacy R. Overby	Technique pour le depistage simultane de deux virus de l'hepatite dans un milieu solide
US4748109A (en) *	1983-07-01	1988-05-31	Baird Phillip J	Assay method and reagent to determine antibodies to papillomavirus virions
FR2560890B1 (fr) *	1984-03-07	1987-10-16	Grp Genie Genetique	Composition utile pour la fabrication de vaccins contenant des particules portant l'antigene de surface du virus de l'hepatite b et le recepteur de l'albumine serique humaine polymerisee, cellules animales capables de produire de telles particules et procede pour leur obtention
JPH073427B2 (ja) *	1985-03-14	1995-01-18	財団法人化学及血清療法研究所	Ｈｂｃ抗体の測定法
EP0341439B1 (fr) *	1988-05-11	1993-08-04	Abbott Laboratories	Procédé pour l'augmentation de la spécificité des immunoessais compétitifs

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BE787014A (fr) *	1971-07-31	1973-01-31	Pfizer	Procede et reactif pour deceler la presence de l'antigene australien
US3867517A (en) *	1971-12-21	1975-02-18	Abbott Lab	Direct radioimmunoassay for antigens and their antibodies
DE2424465C3 (de) *	1974-05-20	1978-03-23	Biotest-Serum-Institut Gmbh, 6000 Frankfurt	Verfahren zum gleichzeitigen Nachweis von Antigenen und deren Antikörpern im Festkörper-Radioimmuntest
US4038378A (en) *	1975-12-22	1977-07-26	Gyaneshwar Prasad Khare	Radioimmunoassay for hepatitis b antigen
AT343822B (de) *	1976-08-20	1978-06-26	Immuno Ag	Radioimmunologisches verfahren und einrichtung zur bestimmung von antigenen

1978
- 1978-02-10 CA CA296,740A patent/CA1100037A/fr not_active Expired
- 1978-02-15 AU AU33322/78A patent/AU3332278A/en active Pending
- 1978-03-01 NL NL7802259A patent/NL7802259A/xx not_active Application Discontinuation
- 1978-03-03 SE SE7802461A patent/SE7802461L/xx unknown
- 1978-03-08 JP JP2554278A patent/JPS53113009A/ja active Pending
- 1978-03-09 FR FR7806854A patent/FR2383446A1/fr active Granted
- 1978-03-10 GB GB9634/78A patent/GB1576981A/en not_active Expired
- 1978-03-10 DE DE19782810506 patent/DE2810506A1/de not_active Ceased

Also Published As

Publication number	Publication date
DE2810506A1 (de)	1978-09-14
GB1576981A (en)	1980-10-15
FR2383446A1 (fr)	1978-10-06
JPS53113009A (en)	1978-10-03
SE7802461L (sv)	1978-09-12
AU3332278A (en)	1979-08-23
NL7802259A (nl)	1978-09-13
FR2383446B1 (fr)	1982-10-29

Legal Events

Date	Code	Title	Description
1998-04-28	MKEX	Expiry

Publication	Publication Date	Title
Mushahwar et al.	1978	Prevalence of hepatitis B e antigen and its antibody as detected by radioimmunoassays
Prince et al.	1973	Specificity of the direct solid-phase radioimmunoassay for detection of hepatitis-B antigen
Smedile et al.	1982	Radioimmunoassay detection of igm antibodies to the hbv‐associated delta (δ) antigen: Clinical significance in δ infection
Nishioka et al.	1991	A high prevalence of antibody to the hepatitis C virus in patients with hepatocellular carcinoma in Japan
Purcell et al.	1973	Microtiter solid-phase radioimmunoassay for hepatitis B antigen
Omata et al.	1978	Comparison of serum hepatitis B surface antigen (HBsAg) and serum anticore with tissue HBsAg and hepatitis B core antigen (HBcAg)
US4356164A (en)	1982-10-26	Detection of non-A, non-B hepatitis associated antigen
Moritsugu et al.	1975	Hepatitis B core antigen: detection of antibody by radioimmunoprecipitation
Hansson et al.	1979	Sites that bind polymerized albumin on hepatitis B surface antigen particles: detection by radioimmunoassay
CA1148859A (fr)	1983-06-28	Technique pour le depistage simultane de deux virus de l'hepatite dans un milieu solide
Arakawa et al.	1982	Maternofetal transmission of IgG-bound hepatitis B e antigen
Madaliński et al.	1979	HBsAg immune complexes in the course of infection with hepatitis B virus
US20100203501A1 (en)	2010-08-12	Assay to detect HCV receptor binding
GB1576981A (en)	1980-10-15	Dane anti-core reagents and assays
Overby et al.	1973	Radioimmunoassay of hepatitis B virus‐associated (Australia) antigen employing 125I‐antibody
Rizzetto et al.	1981	A radioimmunoassay for HBcAg in the sera of HBsAg carriers: Serum HBcAg, serum DNA polymerase activity, and liver HBcAg immunofluorescence as markers of chronic liver disease
Ostrow et al.	1991	Quantitation of hepatitis B surface antibody by an automated microparticle enzyme immunoassay
Kurstak et al.	2013	Human and related viruses
Burrell	1980	Serological markers of hepatitis B infection
Zuckerman	1979	Specific serological diagnosis of viral hepatitis
Prince et al.	1975	A new reversed passive hemagglutination test for detection of HBsAg
AU675502B2 (en)	1997-02-06	One-pot assay
Greenman et al.	1975	A Sensitive Test for Antibody Against the Hepatitis B Core Antigen (Anti‐HBc) 1
Vnek et al.	1979	Cryptic association of e antigen with different morphologic forms of hepatitis B surface antigen
Ben-Porath et al.	1984	Monoclonal antibodies as diagnostic probes in the etiology of hepatitis